APSR2026-478

 
Late-Breaking
Submitted
Poster Presentation
 
AP11-008
P50
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1207170-46904-APSR Severe Asthma_433721.pdf
Format: PDF Only
09. Asthma
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Shu Feng Tan * Hospital Pulau Pinang Department of Respiratory Medicine Georgetown Malaysia
Lalitha Pereirasamy - Hospital Pulau Pinang Department of Respiratory Medicine Georgetown Malaysia
Irfhan Ali Hyder Ali - Hospital Pulau Pinang Department of Respiratory Medicine Georgetown Malaysia
Umadevi A. Muthukumaru - Hospital Pulau Pinang Department of Respiratory Medicine Georgetown Malaysia
Minalosani Arumugam - Hospital Pulau Pinang Respiratory medicine Georgetown Malaysia
Jaya Muneswarao - Hospital Pulau Pinang Department of Pharmacy Georgetown Malaysia
Le Ni Teh - Hospital Pulau Pinang Department of Respiratory Medicine Georgetown Malaysia
Xue Fang Tan - Hospital Pulau Pinang Clinical Research Centre Georgetown Malaysia
 
 
 
 
 
 
 
Presenting Author Details
Shu Feng
Tan
tansf888@gmail.com
+60178720728
31-40
Malaysia
Original Research
Real-world effectiveness of biologic therapy in patients with severe asthma: a single center retrospective cohort study
Maximum 25 words
Abstract Content
Biologic therapies have transformed the management of severe asthma, particularly in patients with type 2 inflammation. However, real-world data on their effectiveness in routine clinical practice remain limited.
We conducted a single-centre retrospective cohort study of patients with severe asthma initiated on biologic therapy. Clinical outcomes were compared between the 12 months pre-biologic and 12 months post-biologic periods. Primary outcome was annual exacerbation rate. Secondary outcomes included oral corticosteroid (OCS) use, including steroid burst frequency and maintenance prednisolone dose, lung function (FEV₁), as well as Asthma Control Test (ACT) score. Continuous variables were expressed as mean ± standard deviation (SD) and analysed using paired t-tests.
A total of 11 patients were included (mean age 59.3 ± 13.6 years; 90.9% female). The cohort demonstrated a type 2 inflammatory phenotype with elevated eosinophil counts and IgE levels. The most commonly used biologic was Dupilumab (45.5%), followed by Benralizumab and Omalizumab (27.3%) respectively. Biologic therapy significantly reduced exacerbation frequency from 6.18 ± 6.91 to 0.64 ± 0.81 (p = 0.021). Steroid burst requirement also decreased significantly (4.00 ± 3.82 vs 0.73 ± 1.01; p = 0.023), alongside a reduction in maintenance prednisolone dose (3.18 ± 3.55 mg vs 0.91 ± 1.69 mg; p = 0.016). ACT scores improved significantly (11.89 ± 3.33 vs 21.56 ± 2.19; p < 0.001). FEV₁ improved from 1.19 ± 0.61 L to 1.52 ± 0.74 L, although this did not reach statistical significance (p = 0.273).
In this real-world cohort, biologic therapy significantly reduced exacerbation frequency and oral corticosteroid use in patients with severe asthma, with a trend toward improved lung function. These findings reinforce the effectiveness of biologic therapy in improving disease control in routine clinical practice.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
real-world study,severe asthma,biologic therapy
maximum 3 keywords and no abbreviations, separated by commas
Nothing to disclosure
293